COX-2: A target for colon cancer prevention

被引：256
|
作者：
Marnett, LJ
DuBois, RN
机构：
[1] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Chem, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Med, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Cell Biol, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA
来源：
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2002年 / 42卷
关键词：
cyclooxygenase; prostaglandins; NSAIDs; cancer; prevention;
D O I：
10.1146/annurev.pharmtox.42.082301.164620
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence: is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention.
引用
收藏
页码：55 / +
页数：26
相关论文
共 50 条
  • [31] Natural COX-2 inhibitors and effects on colon cancer cells
    Pettersson, J.
    Huss, U.
    Karlsson, P. C.
    Choi, Y. H.
    Verpoorte, R.
    Rafter, J. J.
    Bohlin, L.
    PLANTA MEDICA, 2006, 72 (11) : 1066 - 1067
  • [32] COX-2 and colon cancer - Post-presentation discussion
    Taketo
    Mitchell
    INFLAMMATION RESEARCH, 1998, 47 : S116 - S116
  • [33] COX-2 and iNOS, good targets for chemoprevention of colon cancer
    Watanabe, K
    Kawamori, T
    Nakatsugi, S
    Wakabayashi, K
    BIOFACTORS, 2000, 12 (1-4) : 129 - 133
  • [34] Colon cancer and COX-2: remarkable adaptability of cancer cells to their fluctuating microenvironment
    Roberts, H. R.
    Moore, A. M.
    Kaidi, A.
    Williams, A. C.
    Paraskeva, C.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S16 - S16
  • [35] Cyclooxygenase-2 (COX-2) - A therapeutic target in liver cancer?
    Breinig, Marco
    Schirmacher, Peter
    Kern, Michael Andre
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (32) : 3305 - 3315
  • [36] Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer
    G. Aparicio Gallego
    S. Díaz Prado
    P. Jiménez Fonseca
    R. García Campelo
    J. Cassinello Espinosa
    L. M. Antón Aparicio
    Clinical and Translational Oncology, 2007, 9 : 694 - 702
  • [37] Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer
    Gallego, G. Aparicio
    Prado, S. Diaz
    Fonseca, P. Jimenez
    Campelo, R. Garcia
    Espinosa, J. Cassinello
    Aparicio, L. M. Anton
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (11): : 694 - 702
  • [38] Role of COX-2 selective inhibitors for prevention and treatment of cancer
    Amir, M
    Agarwal, HK
    PHARMAZIE, 2005, 60 (08): : 563 - 570
  • [39] COX-2 inhibitors in cancer treatment and prevention, a recent development
    Xu, XC
    ANTI-CANCER DRUGS, 2002, 13 (02) : 127 - 137
  • [40] The role of COX-2 inhibition in breast cancer treatment and prevention
    Arun, B
    Goss, P
    SEMINARS IN ONCOLOGY, 2004, 31 (02) : 22 - 29
12345